CARGO Therapeutics Common Stock (CRGX)

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing innovative treatments for cancer patients in the United States. The company's primary goal is to harness the power of the immune system to fight cancer, and it does this by creating chimeric antigen receptor (CAR) T-cell therapies.

One of the company's lead programs is CRG-022, an autologous CD22 CAR T-cell product candidate that is currently in phase 2 clinical trials. This treatment is designed to overcome resistance mechanisms by targeting CD22, a specific antigen that is commonly expressed in B-cell malignancies. By targeting this antigen, CRG-022 has the potential to provide a more effective treatment option for patients with B-cell cancers.

In addition to CRG-022, CARGO Therapeutics is also developing CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. This approach allows for a more comprehensive attack on cancer cells, increasing the chances of successful treatment.

Formerly known as Syncopation Life Sciences, Inc., the company rebranded as CARGO Therapeutics, Inc. in September 2022. Founded in 2019, CARGO Therapeutics is headquartered in San Mateo, California, and is dedicated to advancing the field of CAR T-cell therapies to improve patient outcomes.

For more information about CARGO Therapeutics and its innovative approach to cancer treatment, visit their website at https://www.cargo-tx.com.